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Safety concerns for fetus development of zidovudine (AZT) administration as prophylaxis 
of vertical transmission of HIV persist. We evaluated the participation of the ATP-binding 
cassette efflux transporter ABCG2 in the penetration of AZT into the fetal brain and the 
relevance for drug safety. Oral daily doses of AZT (60 mg/kg body weight) or its vehicle 
were administered between post gestational days 11 (E11) and 20 (E20) to Sprague-Dawley 
pregnant rats. At E21, animals received an intravenous bolus of 60 mg AZT/kg body 
weight in the presence or absence of the ABCG2 inhibitor gefitinib (20 mg/kg body weight, 
ip) and AZT in maternal plasma and fetal brain were measured by HPLC-UV. ABCG2 
protein expression in placenta and fetal brain, as well as mitochondrial function and 
ultrastructure in fetal brain were also analyzed. In utero chronic exposure to AZT markedly 
induced ABCG2 expression in placenta and fetal brain whereas did not significantly alter 
mitochondrial functionality in the fetal brain. The area-under-the-concentration-time-curve 
of AZT significantly decreased in fetal brains isolated from AZT-exposed fetuses compared 
to control group, but this effect was abolished by ABCG2 inhibition. Our results suggest 
that the absence of mitochondrial toxicity in the fetal brain after chronic in utero 
administration of AZT could be attributed to its low accumulation in the tissue caused, at 
least in part, by ABCG2 overexpression. We propose that any interference with ABCG2 
activity due to genetic, pathological or iatrogenic factors would increase the amount of 
AZT reaching the fetal brain, which could increase the risk of toxicity of this drug on the 
tissue. 































The nucleoside analog reverse transcriptase inhibitor (NRTI) zidovudine (AZT) continues 
to play a key role as a drug for the prevention of maternal-fetal transmission of HIV. 
Prophylactic administration of AZT in combination with a second NRTI and a viral 
protease inhibitor reduces the mother-to-child HIV transmission to 1–2% in developed 
countries (HIV/AIDS, 2013). Unfortunately, exposure to AZT in utero encompasses the 
risk of long term mitochondrial-related toxicity that might be linked to hematological and 
cardiac tissue alteration in children (Barret et al., 2003; European Collaborative Study, 
2004; Pacheco et al., 2006; Sibiude et al., 2015).  
 
Transplacental kinetics of drugs are frequently mediated by ATP-binding cassette (ABC) 
efflux transporters embedded in the maternal face of the placenta (Staud et al., 2012). P-
glycoprotein (ABCB1), multidrug resistance-associated protein 2 and 5 (ABCC2, ABCC5), 
and breast cancer resistance protein (ABCG2) are well-described placental transporters 
affecting the passage of their substrates into the fetal circulation (Ceckova-Novotna et al., 
2006; Hahnova-Cygalova et al., 2011; Meyer zu Schwabedissen et al. 2005a; 2005b). In 
fact, a recent work reported in an in situ model of dually perfused rat placenta showed that 
ABCG2, and at lesser extent ABCB1, could be relevant for the passage of AZT from fetal 
to maternal side (Neumanova et al., 2015). Even though fetal-to-maternal plasma ratio of 
AZT is high (0.63-1.0) in Rhesus macaques and rats (Brown et al., 2003; Patterson et al., 
1997), the transplacental passage of AZT markedly decreases whether AZT is co-
administered with a BCRP substrate as acyclovir (Brown et al., 2003). Furthermore, it has 














expressing ABC transporters from early stages of morphogenesis, such as the brain 
(Saunders et al., 2013, 2012), compared to other fetal organs (Patterson et al., 1997). In 
fact, the central nervous system displays a relative resistance to nucleoside analogs such as 
AZT, in both treatment and toxicity when compared to other organ systems even 
considering that the developing brain is particularly sensitive to mitochondrial damage 
(McCann et al., 2012). In support of a possible participation of ABCG2 in this 
phenomenon, experimental evidence has pointed out that this transporter is expressed at 
higher levels and is functionally more active in the developing than in the adult brain (Ek et 
al., 2012). Additionally, ABCG2 expression has also been found in the fetal brain 
endothelium as early as post-gestational day 12 (E12) in rats (Kalabis et al., 2007).  
 
Moreover, it was shown that the efflux of antiretroviral drugs by ABCG2 seems to become 
of relevance whether a high density of molecules are present in the cell membrane, as 
occurred either in transfected or transformed cell lines (Pan et al., 2007; Wang et al., 2004, 
2003; Weiss et al., 2007) or under in vivo repeated exposure to a substrate as efavirenz 
(Peroni et al., 2011; Roma et al., 2015).  
 
We propose that the low incidence of neurological damage associated with mitochondrial 
dysfunction in children exposed in utero to AZT (Ek et al., 2010) could be related, at least 
in part, to the restriction of AZT passage across both the placenta and the developing blood-
brain barrier by induction of ABCG2. The aim of this study was to analyze whether 
ABCG2 restricts the accumulation of AZT in fetal brain after chronic in utero exposure in 














AZT administration leading to overexpression of ABCG2 in placenta and fetal brain that 
induced the efflux of AZT out of the fetal brain.  
 
1. Materials and methods 
1.1.  Materials 
AZT was provided by Laboratorios Richmond (Buenos Aires, Argentina). Gefitinib was 
obtained from Astra-Zeneca (Chesire, UK). Protease inhibitor cocktail (Complete mini, 
Roche Applied Science, Mannheim, Germany) and phenylmethylsulfonyl fluoride (PMSF, 
Sigma-Aldrich, St. Louis, MO) and every other chemical not listed here were of the highest 




1.2.1. Animals and treatments 
Female Sprague-Dawley rats (8 weeks, 150-200 g body weight) were housed under a 
12:12-h light:dark cycle, at controlled room temperature with food and water ad libitum. 
All procedures involving animals were conducted in accordance with NIH guidelines for 
the Care and Use of Laboratory Animals (Institutional Animal Care and Use Committee 
Guidebook, 2nd ed., 2002). The 3Rs principle of Reduction, Refinement, and Replacement 
was considered in the design of the animal experiment and applied when possible. Animal 
treatment was carried out in accordance with the guidelines of the 6344/96 regulation of the 
Argentinean National Drug, Food and Medical Technology Administration (ANMAT). 
Pregnancy was confirmed by the presence of sperm in the vaginal smear the morning after 














E15, E18 or E21 (n=3 per group) were used in this study.  The day of the assay, rats were 
anaesthetized with 1.2 g/kg urethane (i.p.) and subsequent doses of anesthesia were 
administered as needed. A laparotomy was performed and a small incision was made in the 
uterine wall to allow for sampling of the pups.  
Treatments: Twenty-four pregnant rats were randomly divided into two groups, given either 
60 mg / kg body weight zidovudine (AZT) or vehicle (0.05% ethanol in saline solution) 
from E11 to E20 orally by esophageal catheter. In E21, the animals from each group were 
again divided into two subgroups for the administration of the selective inhibitor of 
ABCG2 gefitinib (GFT, 20 mg/kg) or vehicle (dimethyl sulfoxide:propylene glycol:saline 
solution, in a 2:2:1 ratio), respectively, 30 min before the onset of pharmacokinetic assays. 
In this way, 4 groups were constituted: VEH / VEH, AZT / VEH, VEH / GFT, and AZT / 
GFT (n = 6 per group). 
 
2.2.3. ABCG2 protein expression levels and localization 
2.2.3.1. Western Blot in placenta and fetal brain 
Placenta (at E11, E15, E18, and E21) and fetal brain (E18 and E21) were collected from 
pregnant rats within 30 min of surgery and immediately stored at -70° C. To prepare 
samples for western blotting analysis, total protein was obtained from tissues defrosted on 
ice and measured with bovine serum albumin (BSA, A7906 Sigma-Aldrich, USA) as 
standard (Lowry et al., 1951) and analyzed as previously described (Peroni et al., 2011). 
Briefly, placenta from E11 and E15 (pool of three, 30 μg of protein per line), E18 and E21 
(30 μg of protein per line), and fetal brain from E18 and E21 (pool of three; 50 μg of 
protein per line) were loaded onto 8 % SDS-polyacrylamide gels, subjected to 














were cut at molecular mass 52 kDa, based on the Kaleidoscope molecular weight standards 
(Bio-Rad, Hercules, CA, USA). The upper and lower portions were then incubated 
overnight at 4° C with anti-rat ABCG2 antibody (M-70, 1:400; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) or mouse anti-ABCG2 antibody (BXP-21 clone 1/400, Santa Cruz 
Biotechnology, CA, USA, SC-58222) and anti-actin antibody (A2066, 1:1000; Sigma-
Aldrich, USA), respectively. The immune complex was detected by incubation with the 
horseradish peroxidase-linked anti-rabbit antibody (sc-2004, 1/2000; from Santa Cruz 
Biotechnologies) or horseradish peroxidase-linked goat anti-mouse IgG (sc-2031, 1/2000; 
from Santa Cruz Biotechnologies) during 90 min. The bands were detected by 
chemiluminescence (Amersham ECL Biosciences, Amersham, UK) and quantified by 
densitometric analysis using ImageJ software (1.34S, US National Institutes of Health, 
Bethesda, MD, USA). 
 
2.2.3.2. Immunofluorescence in fetal brain tissue 
Fetus obtained by cesarean surgery on E21 were decapitated and the brain were carefully 
removed from skull, washed in cold 0.1 M K2HPO4/KH2PO4, pH 7.4 (PB), placed in a pre-
chilled glass platen, and cleaned to remove meninges and choroid plexus. One hemisphere 
of each brain was postfixed in 4% paraformaldehyde / PB at 4 °C for 24 h, cryoprotected 
overnight in 30% sucrose/PB. Four serial hemi-coronal slices (20-μm thickness) at 3 mm 
(striatal level) from the frontal tip were performed with a rotary microtome cryostat 
(Thermo Scientific), mounted in gelatinized glass slides and stored at −20°C until use. Two 
section of each series was stained with hematoxylin and eosin (H&E) according to standard 
protocols and observed at under low as well as 200 × magnification. For 














serum (FCS) in phosphate saline buffer (PBS) for 1 h prior incubation with mouse anti-
ABCG2 antibody (BXP-21 clone 1/100, Santa Cruz Biotechnology, SC-58222) overnight 
at 4 °C. The BXP-21 antibody clone has previously been shown to specifically react with a 
72 kDa protein in rat fetal brain (Ek et al., 2010). Slides were incubated with goat anti-
mouse IgG (Fc specific)–biotin antibody (1/250 Sigma Aldrich, B7401) overnight at 4 °C, 
followed by 1 h incubation with DTAF-streptavidin (1/500 Jackson ImmunoResearch 
Laboratories Inc, TechFAQ #6) at room temperature. All antibodies were diluted in 3% 
FCS/0.3% Tween20 PBS and three washes with 0.3%-Tween20 PBS were performed 
between each step. Tissues were mounted with Mowiol and coverslipped. Control sections 
omitting primary antibody were prepared in each slide and were always blank. Photographs 
were taken with an optical microscope (Nikon Eclipse) equipped with fluorescent optics 
and a camera connected to a monitor and computer. Digital images were color balanced 
with Adobe Photoshop 8.0 (Adobe Systems). The average intensity value of each particle 
was background subtracted using the average intensity of an adjacent region of comparable 
size.  
 
2.2.4.  Mitochondrial function and structure  
2.2.4.1. Isolation and preparation of mitochondrial membranes 
Mitochondrial purified fractions from fresh fetal brain homogenates isolated from E21 pups 
treated with AZT or its vehicle (n=4 per group) were obtained by differential centrifugation 
in a Sorvall RC5C centrifuge (Sorvall, Buckinghamshire, England). Five fetal brains were 
pooled, washed, and minced in ice-cold STE buffer [250 mM sucrose, 5 mM Tris-HCl, and 
2 mM EGTA (pH 7.4)]. Samples were homogenized in 1:10 STE buffer and centrifuged at 














supernatant by a second centrifugation step at 8000g for 10 min. Finally, the pellet was 
washed, rinsed, and resuspended in 500 μL of STE buffer. The whole procedure was 
carried out at 0-4 °C (Mela and Seitz, 1979). Mitochondrial membranes were obtained by 
three freeze-thaw cycles of the mitochondrial preparation, followed by a homogenization 
step by passage through a 29G hypodermic needle (Boveris et al., 2002).  
 
2.2.4.2 Mitochondrial respiration  
Mitochondrial oxygen consumption was assessed by polarography using a Clark-type 
oxygen electrode (Hansatech Oxygraph, Hansatech Instruments Ltd, Norfolk, England) for 
high resolution respirometry at 30 °C. Freshly isolated brain mitochondria (1 mg 
protein/mL, n=4 per group) were incubated in respiration buffer [120 mM KCl, 5 mM 
KH2PO4, 1 mM EGTA, 3 mM HEPES, and 1 mg/mL fatty acid-free BSA (pH 7.2)] 
supplemented with 2 mM malate and 5 m  glutamate, or 8 mM succinate. An initial rest 
state respiration (state 4) was established under these conditions, which was then switched 
to active state respiration (state 3) by the addition of 1 mM ADP. Respiratory control ratio 
(RCR) was calculated as state 3/state 4 respiration rates. Results were expressed as ng-at 
O/min mg protein (Boveris et al., 1999). 
 
2.2.4.3. Mitochondrial respiratory chain complexes activity 
 The enzymatic activity of mitochondrial respiratory complexes was evaluated by a 
colorimetric assay in a Beckman DU 7400 diode array spectrophotometer (Beckman 
Coulter Inc., CA, USA). Mitochondrial membranes (0.25 mg protein/mL) were incubated at 
30 °C in 100 mM PBS (pH 7.2). For complexes I and II, reaction x was supplemented with 














and 0.5 mM KCN. Cytochrome c3+ reduction rate was followed at 550 nm (ε = 19 mM-1 
cm-1) and results were expressed as nmol reduced cytochrome c3+/min mg protein. For 
complex IV, reaction buffer was instead supplemented with 60 μM cytochrome c2+. In this 
case, cytochrome c2+ oxidation rate was calculated from the pseudo-first reaction constant 
(k´) and expressed as k´/mg protein (Yonetani, 1967). 
 
2.2.4.4. Mitochondrial membrane potential 
Freshly isolated brain mitochondria (25 μg protein/mL, n=4 per group) were incubated with 
the potentiometric cationic probe 3,3′-dihexyloxacarbocyanine iodide (DiOC6) (30 nM) in 
respiration buffer. The procedure was performed in the dark at 37 °C for 20 min. After the 
incubation period, mitochondria were acquired in a FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA, USA). To exclude debris, samples were gated based on light-
scattering properties and 20,000 events per sample within this gate were collected. 10-N-
nonyl acridine orange (NAO) (100 nM) was used to selectively stain mitochondria and to 
evaluate their purity, due to its ability to selectively bind to cardiolipin at the inner 
mitochondrial membrane (Haines and Dencher, 2002). Samples were analyzed in the FL-1 
channel with FlowJo software (Tree Star, Ashland, OR, USA), and the arithmetic mean 
values of the median fluorescence intensities (MFI) were obtained. Autofluorescence 
(negative control) was evaluated in isolated brain mitochondrial samples without DiOC6. 
Total depolarization induced by carbonyl cyanide m-chlorophenyl hydrazine (m-CCCP) (2 
μM) was used as a positive control. Mitochondrial preparations that showed no changes in 
membrane potential under this condition were discarded (Marchini et al., 2013). 
 














2.2.4.5.1. Tissue preparation for transmission electron microscopy 
 
Fetus removed by cesarean surgery on E21 were decapitated and brains were carefully 
removed, washed in chilled PB and placed in a pre-chilled glass platen. Four pieces of 1-2 
mm3 were obtained from four different areas of the cerebral cortex and fixed with 2.5% 
glutaraldehyde/PB for 4 h. Samples were postfixed in 1% osmium tetroxide/PB for 1.5 h at 
0 °C. Samples were contrasted with 5% uranyl acetate for 2 h at 0 °C, dehydrated, and 
embedded in Durcupan resin (Fluka AG, Switzerland) for 72 h at 60 °C. Ultrathin sections 
were cut and observed with a Zeiss EM 109 transmission electron microscope 
(Oberkochen, Germany). Representative digital images were captured using a CCD 
GATAN ES1000W camera (CA, USA). 
 
2.2.4.5.2. Electron microscopic evaluation 
Random sections were selected for analysis by an electron microscopy technician blinded 
to the treatments. Using the “point counting grids” methodology (Vanasco et al., 2014), 
mitochondrial density was determined. For each sample, 10 photomicrographs at 85,000X, 
were evaluated for mitochondrial morphology. The degree of mitochondrial pathology was 
scored by two different investigators, all of whom were given coded photomicrographs to 
eliminate bias. Scoring paradigm for mitochondrial status in brain cortex is detailed in 
legend at Figure 3.  
 















 The TBARS assay is the classical approach in order to evaluate the extent of lipid 
peroxidation processes in biological samples (Yagi, 1976). Briefly, 100 μL of brain 
homogenates were mixed with 200 μL 0.1 N HCl, 30 μL 10% (w/v) phosphotungstic acid 
and 100 μL 0.7% (w/v) 2-thiobarbituric acid, and incubated at 95 °C for 60 min. 
Afterwards, samples were cooled and TBARS were extracted in 1 mL of n-butanol. After a 
10 min centrifugation at 800 g, the fluorescence of the butanol layer was measured in a 
Perkin Elmer LS 55 luminescence spectrometer (Perkin Elmer, MA, USA) at 515 nm 
(excitation) and 553 nm (emission). A calibration curve was prepared using 1,1,3,3-
tetramethoxypropane as standard. Results were expressed as nmol TBARS/mg protein.  
 
2.2.6.  Pharmacokinetic analysis 
 2.2.6.1. Sample collection 
For pharmacokinetic assays, rats were anaesthetized with urethane (1.2 g/kg, i.p and 
supplemented to loss of reflexes). Prior to dosing, a laparotomy was performed and a small 
incision was made in the uterine wall to allow for sampling of the pups, and cannulas were 
surgically implanted in the right femoral vein and in the carotid artery 
The pharmacokinetic study consisted of an intravenous administration through the femoral 
vein of 60 mg / kg AZT (0.05% ethanol in saline solution) and its concentration in maternal 
blood and fetal brain was determined at times 0, 1, 2, 5, 10, 15, and 30 min. The dose was 
selected on the basis of a previous study that shows quantifiable values of AZT in placenta, 
amniotic fluid as well as in total fetal tissue homogenates (Brown et al., 2003). For each 
point, 150 µl of heparinized maternal blood was collected by carotid artery and 1 fetal sac. 
Body temperature was maintained by heated surgical pads and incandescent lights. The 














Blood was placed into heparinized tubes. Fetal brains were isolated from the pups and 
homogenized in 2 volumes of deionized water (wt/vol). Proteins were precipitated by 
addition of 15% trichloroacetic acid on ice for 15 min with vortex and then centrifuged 10 
min at 5000g. Supernatants were stored at 70°C until analysis.  
 
2.2.6.2. Quantification of AZT in biological samples: Instrumentation: he HPLC system 
consisted in a Spectra series P100 pump (Thermo separation products, Virginia, USA), with 
a 20 μL injection loop. Separation was performed using a Luna C8 column (250 X 4.6 mm, 
5 μm particle size, Phenomenex, CA, USA) for AZT samples. 
Chromatographic conditions: Isocratic elution at room temperature; flow rate: 1.2 ml/min. 
UV Detection: 266 nm for AZT. Mobile phase: 20 mM sodium phosphate buffer 
(containing 8 mM 1-octanesulfonic acid sodium salt)–acetonitrile (86:14, v/ v) with pH 
adjusted to 3.2 with phosphoric acid (Fan and Stewart, 2002). Samples were injected in 
duplicate into the HPLC column.  
Pharmacokinetics analysis: All data were analyzed using the freely available menu-driven 
add-in program for Microsoft Excel PKsolver (Zhang et al., 2010). A non-compartamental 
analysis was performed for concentration-time profiles data and area under the curve of 
AZT from 0 to infinity (AUC AZT0∞) for each sample were extracted. 
 
2.2.7. Statistical analyses 
 Data are presented as the mean ± S.E.M. (n = 4 to 6) analyzed with Graph Pad Prism 5 
(Graph Pad Software). Pharmacokinetic assays were analyzed by two-way analysis of 














analyzed by one-way analysis of variance followed by Bonferroni's multiple comparison 
test. TBARS assay, mitochondrial respiration, respiratory complexes activities, 
mitochondrial potential and mitochondrial ultrastructure were analyzed by Student t-test. 
 
3. Results 
3.1. Effect of AZT on the expression of ABCG2 in placenta and fetal brain  
To validate our experimental model, a time course of ABCG2 protein expression in 
placenta was performed in control Sprague-Dawley rats from middle to term gestation 
covering the period in which the animals would be subsequently treated with AZT (E11 to 
E21). A band of approximately 72 kDa corresponding to the molecular weight of the 
monomer of ABCG2 was observed in placenta. As shown in Supplemental File 1A, 
ABCG2 showed maximal expression at E15 although the difference failed to reach 
statistical significance respect to E11. From E15 to hereinafter ABCG2 significantly 
decreased becoming almost undetectable in E21 (Supplemental File 1A and B). Moreover, 
a significant decreased in ABCG2 expression was also observed in fetal brains between 
E18 and E21 (Supplemental File 1A and B). 
To evaluate the effect of chronic exposure to AZT, pregnant rats were treated with 60 
mg/kg body weight AZT or its vehicle (0.05 % ethanol in saline solution) daily by gavage 
from E11 to E20. Expression of ABCG2 in the placenta and fetal brain of vehicle-treated 
animals was not significantly different from that found in control animals (Figure 1A and 
B). A significant induction of ABCG2 protein in both tissues was observed in rats 
chronically exposed to AZT compared to vehicle-treated animals (Fig. 1B). When we 
performed a histological analysis in fetal brain slices from both groups by the H&E 














developing striatum did not show differences between those tissues obtained from rats 
treated with vehicle compare with those treated with AZT (Fig. 1C and F). 
Immunofluorescence for ABCG2 performed in the same area of the brain showed a higher 
immunoreactivity for the protein in fetal brains isolated from rats chronically exposed to 
AZT (Fig. 1D) respect to vehicle-treated ones (Fig. 1 G). At higher magnification (Fig. 1E 
and H), it could be observed that immunoreactivity for ABCG2 in the fetal brain cortex was 
exclusively localized to blood vessels structures in accordance to that observed by Ek et al 
(Ek et al., 2010). 
 
3.2. Effect of chronic oral administration of AZT in the functionality and 
ultrastructure of fetal brain mitochondria  
Since AZT causes alterations in the mitochondrial energy-generating mechanism 
(Szewczyk and Wojtczak, 2002), we analyzed oxygen consumption in freshly isolated 
mitochondria from fetal brain. We did not observed modifications in the respiratory 
consumption ratio (RCR) using malate plus glutamate, or succinate, as respiratory 
substrates in brain mitochondria isolated from pups exposed in utero to AZT respect to the 
vehicle-treated ones (Table 1). In addition, as shown in Table 2, no changes were detected 
when the activity of the respiratory chain complexes I or II were assessed, whereas a slight 
but no significant increase in Complex IV was found in the AZT-exposed group.  
Mitochondrial membrane potential comprises another key feature of mitochondrial 
function. Isolated brain mitochondria were selected from background based on light-
scattering properties (SSC vs FSC, Fig. 2A) and gated events were chosen for analysis. In 
every analyzed preparation, >95% of gated events were NAO-positive compared with 














constituents throughout the isolation procedure was kept at minimum. Moreover, no 
significant differences were observed in NAO MFI between control and AZT-exposed pups 
(Fig. 2C). Regarding mitochondrial membrane potential, as it is shown in DiOC6 overlaid 
histograms (Fig. 2D) and quantification as MFI (Fig. 2E), no significant differences were 
also observed between control and AZT-exposed pups.  
We also analyzed the mitochondrial ultrastructure of the fetal cerebral cortex in E21. 
Several parameters of mitochondrial damage were observed in tissues isolated from 
animals treated either with vehicles (Fig. 3A-E) or chronically exposed to AZT (Fig. 3F-J), 
such as those detailed in the legend of Figure 3. The results of mitochondrial damage score 
quantification, performed by two investigators on a total of 10 tissue photomicrographs at 
85000x magnification (Fig. 3E and J) and in turn in duplicate, showed that there were no 
significant differences in the mitochondrial status of the cerebral cortex between the treated 
and vehicle groups (Fig. 3K). 
 
3.3. Lipidic peroxidation in fetal brain homogenate 
Another parameter of mitochondrial damage is the over production of reactive species of 
oxygen that leads to oxidative damage to lipids. Furthermore, in our experimental 
conditions, no significant changes in TBARS levels were observed in fetal brain 
homogenate of fetuses isolated from mothers treated with AZT respect to the animals 
receiving vehicle (Fig. 3L) precluding an over extent of lipid peroxidation processes. 
 
3.4. Effect of chronic oral administration of AZT on its accumulation in the 














In order to evaluate the passage of AZT to fetal brain in our model and the participation of 
ABCG2, we proceeded to administer an i.v. dose of 60 mg AZT/kg body weight in term-
pregnancy rats chronically exposed to either the drug or the vehicle in control conditions of 
after a 30 min-pre administration of the selective inhibitor of ABCG2 gefitinib [20 mg/kg 
i.p.; (Roma et al., 2015)]. Drug levels were quantified in maternal blood as well as in fetal 
brain at different times by HPLC-UV. No detectable levels of AZT were found at time 0 in 
either maternal blood or fetal brain in samples obtained from animals chronically treated 
with AZT. No differences were found in the concentration-versus-time curves for AZT in 
maternal blood between vehicle groups and chronically exposed to AZT (Fig 4A), even in 
the presence of the inhibitor of ABCG2 gefitinib (Fig 4B). In addition, Figure 4C shows 
that inhibition of ABCG2 does not modify AZT levels in maternal blood, as no changes 
were observed in the corresponding area under the curve from 0 to infinite in maternal 
plasma (AUC 0∞ plasma; Fig. 4C).  
Unlike what was observed in maternal plasma, Fig. 5A, the kinetic profile and the AUC0∞ 
of AZT in fetal brains from pups chronically exposed in utero to AZT was significantly 
reduced with respect to the vehicles in control conditions (Fig. 5A). Nevertheless, this 
difference disappeared after ABCG2 inhibition (Fig. 5B), which was also reflected in 
changes in the accumulated amount of drug in the tissue represented as the area under the 
curve (AUC0∞) in Fig. 5C, suggesting that induction of ABCG2 have a relevant 
participation in limiting the penetration of AZT in the fetal brain. 
Moreover, the concentration of AZT in fetal brain and maternal blood showed no difference 
















The goal/aim of this study was to evaluate the in vivo contribution of the efflux transporter 
ABCG2 to the delivery of the substrate AZT towards the fetal brain using a model of 
chronic oral administration of the drug in pregnant rats. We have found that sustained 
exposure to AZT induced ABCG2 in placenta and fetal brain. Moreover, decreased 
accumulation of AZT in fetal brain, because of an efflux mechanism due to the induction of 
ABCG2, would account for the absence of mitochondrial toxicity that we found in this 
tissue. Our results are in accordance with the low prevalence of adverse neurologic effects 
compared to other organs, such as heart, muscle, and blood cells, in infants exposed to the 
NRTIs in utero (King, 2004). In this sense, it has been shown that high experimental AZT 
doses are required to cause neurologic abnormalities in fetuses chronically exposed to AZT 
(McCann et al., 2012). 
ABC transporters collaborate with the elimination of lipophilic compounds that reach the 
fetal compartment (Figueroa et al., 2010; Löscher and Potschka, 2005). ABCG2 is highly 
expressed in placenta in several species (Maliepaard et al., 2001), but it undergoes 
substantial changes during normal placental development (Hahnova-Cygalova et al., 2011). 
From E11 to E21 in rats, that could be extrapolated to the time window in which AZT is 
recommended for the prophylaxis of vertical transmission of HIV in women, we found that 
placental ABCG2 gradually decreased to become almost undetectable near to parturition 
(Figure 1A, 1B). This is in agreement with previous works in rats, mice and humans (Wang 
et al., 2006; Yasuda et al., 2005). In turn, the present observation that ABCG2 in fetal brain 
decreased from E18 to E21 (supplemental file 1) is in accordance with previous reported 














side of epithelial cells of brain in early fetal stages at higher levels than in postnatal days 
giving additional neuroprotection to that provided by the placenta (Ek et al., 2010). 
 
AZT disposition between mother and fetus have shown to be poorly modulated by ABCG2 
when tested in rat term placenta (Neumanova et al., 2016) with almost undetectable levels 
of the transporter as previously reported (Mao, 2008) and in the present work (Figure 1). 
Even so, pharmacokinetics of AZT in near-term pregnant rats adjusted to a two-
compartment model with first order elimination, but when it is co-administered with the 
ABCB1/ABCG2 substrate acyclovir (Gunness et al., 2011), an increased access of both 
drugs to fetal tissues is observed (Brown et al., 2003), suggesting that ABC transporters 
could act as fetal barriers mechanisms (Brown et al., 2003). Since AZT is both substrate 
and modulator of ABCG2 in vitro (Wang et al., 2004, 2003), it could be possible that in 
conditions coursing with higher levels of ABCG2, this transporter could restrict AZT 
disposition. In this sense, no histologic alterations, at least at striatal level, were found in 
fetal brains exposed in utero to AZT in our model (Fig 1 C and F).  An induction of 
ABCG2 could be attained by sustained substrate exposure, as we previously observed for 
the overexpression of ABCG2 in small intestine and blood-brain barrier caused by 
efavirenz (Peroni et al., 2011; Roma et al., 2015) as well as in the placenta and in the fetal 
brain (present work, Fig 1A and 1B). Moreover, immunofluorescence showed that an 
specific mark for ABCG2 localized in blood vessels structures in the cortex fetal brain (Fig 
1C-F; (Ek et al., 2010) confirms the presence of this transporter in the developing brain-















The amount of AZT that can cross placenta and reaches fetal circulation is relevant for 
mitochondrial function. It was reported that AZT alters the enzymes involved in 
mitochondrial energy production by a short-term oxidative stress-mediated mechanism 
(Szabados et al., 1999) and affects mitochondrial proteins synthesis through long-term 
damage of mitochondrial DNA (Szewczyk and Wojtczak, 2002). In our model, in utero 
exposure to AZT during the second half of gestation did not cause alterations in 
mitochondrial function assessed through mitochondrial oxygen consumption, respiratory 
chain complexes activity, and inner membrane potential (Table 1, Table 2 and Figure 2). In 
addition, the absence of AZT exposure-related alterations of mitochondria ultrastructure in 
fetal brain found reported here (Fig 3A-K) is consistent with findings in primates exposed 
to AZT in utero, where mitochondrial brain compromise is observed only whether AZT is 
associated to other NRTIs perinatally (Divi et al., 2010; Gerschenson et al., 2000). The 
present findings that show preserved functionality and structure in mitochondria, are in 
agreement with previously published studies designed to examine neurodevelopment in 
infants born to HIV-1–infected mothers, since it has not been reported 
neurodevelopmental/cognitive compromise that is due only to HAART exposure (Alimenti 
et al., 2006). In turn, the absence of alterations in the lipidic peroxidation parameters in the 
brain tissue of fetuses exposed in utero to AZT with respect to the vehicles (Fig. 3L) is 
another present finding that reinforces the absence of fetal brain damage observed in our 
model and which may be related to low tissue exposure to the drug. Supporting this 
observation, is the present finding showing a marked decrease of AZT concentrations in 
fetal brain in chronic-exposed animals (Fig. 5) without changes in the levels of AZT in 
maternal blood (Fig 4). In accordance with this, a low penetration of the ABCG2 substrate 














hypothesis that induction of ABCG2 restrict the access of AZT to fetal brain was confirmed 
by the significant increase (nearly 70 %) in AZT levels in fetal brains from chronically-
treated drug pregnant rats, that equated those found in vehicles, when ABCG2 was 
inhibited by gefitinib (Fig 5B and 5C). Moreover, this increase in AZT levels in fetal brain 
occurred at the expense of an inhibition of ABCG2 at both the placenta and fetal brain since 
maternal blood concentrations remained unchanged, as demonstrated by increased AUC fetal 
brain /AUC maternal blood ratio (Fig. 5D). On the other hand, the absence of changes in the 
animals treated with vehicles could likely be due to the almost null expression of ABCG2 
in the placenta and the fetal brain of these animals. Still, it is not excluded that there is 
another efflux transporter that regulates the AZT passage through the placenta or the blood-
brain barrier. 
 
The relevance of ABCG2 on AZT fetal disposition seems to be dependent on variables that 
affect the transporter expression levels or activity. Possible scenarios are the combination 
of AZT with either the ABCG2 inhibitor ritonavir (Bierman et al., 2010) or the ABCG2 
substrates nitrofurantoin and sulfasalazine, which are commonly prescribed for pregnant 
women that  have been shown to have ABCG2 activity-depending pharmacokinetics 
(Goldberg et al., 2015; Lee et al., 2015; Ni et al., 2010) as well as ABCG2 gene 
polymorphisms (Mao, 2008).  
We consider that to be able/in order to minimize the risk of toxicity affecting newborns, it 
is of interest to understand all factors potentially affecting AZT disposition in fetus. , Co-
administration of AZT with other ABCG2 substrates or inhibitors with narrow therapeutic 














factors that would increase the amount of AZT reaching the fetal brain, increasing  the risk 
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Figures and Table legends 
 
Figure 1. Effect of chronic AZT on the expression of ABCG2 in placenta and fetal 
brain 
(A) Representative immunoblots for ABCG2 and actin performed in placenta (left) or fetal 
brain (right) at post gestational day E21 isolated from control pregnant rats or after chronic 
oral administration of either AZT (60 mg/kg) or vehicle (0.05% ethanol). (B) 
Corresponding semi quantification for control (white bars, n=3), vehicles (VEH, squared 
bars, n=6) or AZT (stripped bars, n=6) in placenta (left) or fetal brain (right). Data are 
presented as media ± S.E.M relative densitometric units calculated as ratio between optical 
density of ABCG2 (mouse anti-ABCG2 antibody; BXP-21 clone, 1/400) and actin (n=6 
different litters for each group). Statistically significant difference (**p<0.001 for placenta; 
*p<0.01 for fetal brain) between AZT and either CONTROL or VEH. Histology: 
Representative images of H&E-stained hemi-coronal sections at the striatal level from fetal 
brain at E21 isolated from animals chronically exposed either to vehicle (0.5% ethanol, C) 
or to 60 mg/kg AZT (F), n=4 per group. The scale bar in the inset represents 1 mm, whereas 
the area delimited by the black box is shown amplified to 200x magnification. 
Immunofluorescence of ABCG2: Representative photomicrographs of 20 µm-thickness 
cryosections from fetal brain at E21 isolated from VEH (D, E) or AZT (G, H), n=4 per 
group. Photomicrographs of the striatal region are shown at 100X (D and G) and 
















Table 1. Effect of chronic oral administration of AZT in mitochondrial function in 
fetal brain. Oxygen consumption rates were evaluated by high-resolution respirometry in 
isolated mitochondria from fetal brain. 2 mM Malate plus 5 mM glutamate, or 8 mM 
succinate, were used as respiratory substrates to establish state 4 respiration. Afterwards, 1 
mM ADP was added to archive state 3 metabolic state. RCR was calculated as state 3/state 
4 respiration rates. RCR: respiratory control ratio 
 
Table 2. Effect of chronic oral administration of AZT in mitochondrial respiratory 
chain complexes activity. Colorimetric assessment of mitochondrial respiratory chain 
complexes activity, based on cytochrome c3+ reduction for Complexes I and II, and on 
cytochrome c2+ oxidation for Complex IV, in mitochondrial membranes isolated from fetal 
brains of either vehicle (VEH, white bars) or AZT (stripped bars) treated pregnant rats in 
E21. 
 
Figure 2. Evaluation of isolated brain mitochondrial membrane potential by flow 
cytometry.  
(A) Mitochondria were selected based on light scattering properties and 20,000 gated 
events were collected. (B) Overlaid histograms and (C) fluorescence quantification of gated 
mitochondrial events for NAO, indicating purity of the mitochondrial preparations and 
cardiolipin oxidation. Autofluorescence (grey), control (light orange), AZT (dark orange). 
(D) Overlaid histograms and (E) fluorescence quantification of gated mitochondrial events 
for DiOC6, indicating mitochondrial inner membrane potential. Autofluorescence (grey), 















Figure 3. Effect of chronic AZT on mitochondrial ultrastructure and lipid oxidation in 
fetal brain.  
Representative electron microscopy photomicrographs (30,000X) of fetal brain cortex at 
E21 after in utero chronic exposure to 60 mg/kg body weight AZT (F-I) or vehicle (0.05% 
ethanol, A-D). Boxes in B and G are shown at greater magnification (85,000X) in F and J, 
respectively. The photos show swelling of mitochondria (blue arrow), dissolution of some 
cristae (violet arrow) or light matrix (red arrow) and disruption of mitochondrial 
membranes (green arrow). (K) Quantification of mitochondrial damage in brain cortex from 
VEH (white bar) or AZT (stripped bar) groups. Ten photomicrographs per sample (n=3 per 
group by duplicated) were analyzed based on the followed scoring: 0- Mitochondrion with 
intact membrane, compact, well-defined cristae, and a dark matrix. 1- Mitochondrion with 
light matrix. 2- Mitochondrion with cloudy swelling. 3- Amorphous material collection 
inside the mitochondrion. 4- Mitochondrion membrane rupture. (L) Lipid oxidation was 
evaluated by the TBARS assay in fetal brain homogenates, from either vehicle (VEH, white 
bars) or AZT (stripped bars) treated pregnant rats in E21.  
 
Figure 4. Effect of chronic oral administration of AZT on its pharmacokinetic in 
maternal blood  
Kinetics of AZT in maternal blood after an i.v. administration of 60 mg AZT/kg body 
weight to pregnant rats at E21 after repeated oral administration of AZT (black circles) or 














administration of the ABCG2 inhibitor gefitinib (20 mg/kg body weight; GFT; B) or the 
corresponding vehicle (dimethyl sulfoxide:propylene glycol:saline solution, in a 2:2:1 ratio, 
respectively; VEH; A). Data are presented as mean ± SEM of the μg AZT/ml for each time 
point. (C) Area under the curve of AZT from 0 to infinite in maternal blood (AUC AZT0∞ 
plasma) after repeated oral administration of AZT or its vehicle in the presence (AZT / GFT 
and VEH / GFT, respectively) or absence (AZT / VEH and VEH / VEH, respectively) of 
gefitinib. Data is presented as mean ± SEM of the μg. ml-1 min-1 of AZT for 6 animals per 
group. 
 
Figure 5. Effect of chronic oral administration of AZT on its accumulation in the 
distribution to the fetal brain 
Kinetics of AZT in fetal brain after an i.v. administration of 60 mg AZT/kg body weight to 
pregnant rats at E21 after repeated oral administration of AZT (black circles) or its vehicle 
(open circles) from t1 to t30 min. Assays were onset after 30 min of an i.p. administration 
of the ABCG2 inhibitor gefitinib (20 mg/kg body weight; GFT; B) or the corresponding 
vehicle (dimethyl sulfoxide:propylene glycol:saline solution, in a 2:2:1 ratio, respectively; 
VEH; A). Data are presented as mean ± SEM of the μg AZT/ml for each time point, 
*p<0.05; **p<0.01 between VEH / VEH and AZT / VEH for each time point in control 
conditions. (C) Area under the curve of AZT from 0 to infinite in fetal brain (AUC AZT0∞ 
fetal brain) after repeated oral administration of AZT or its vehicle in the presence (AZT / GFT 
and VEH / GFT, respectively) or absence (AZT / VEH and VEH / VEH, respectively) of 
gefitinib. Data is presented as mean ± SEM of the μg. ml-1 min-1 of AZT for 6 animals per 














VEH and AZT / GFT groups. (D) AUC AZT0∞ fetal brain/ AUC AZT0∞ plasma ratio. 
ap<0.001 between VEH / VEH and AZT / VEH groups; bp<0.001 between AZT / VEH and 
AZT / GFT groups. 
 
Supplemental File 1. 
(A) Representative immunoblot for ABCG2 (72 kDa) and actin (42 kDa) performed in 
placenta at E11, E15, E18 or E21 (left) and fetal brains at E18 or E21 (right) from 
control pregnant rats. (B) Corresponding semi-quantification presented as media ± 
S.E.M relative densitometric units calculated as ratio between optical density of 
ABCG2 (polyclonal anti-rat ABCG2 antibody M-70, 1/400) and actin (n=3 pregnant 
rats for each gestational day). For placenta (left): a= different from E11 with p<0.001, 
b= different from E15 with p<0.001; for fetal brain (right): *=p<0.01 between E18 and 














































































































































Table 1. Mitochondrial oxygen consumption 
 
 VEH AZT 
Malate + Glutamate   
State 4 11 ± 1 13 ± 2 
State 3 55 ± 4 58 ± 14 
RCR 5,1 4,2 
   
Succinate   
State 4 23 ± 4 26 ± 6 
State 3 69 ± 10 71 ± 20 
RCR 3,0 2,7 
 



























VEH 203 ± 8 60 ± 4 113 ± 10 




















 -AZT induced the expression of ABCG2 in the placenta and the fetal brain.  
 -Induction of ABCG2 restricted AZT disposition in the fetal brain. 
 -Induction of ABCG2 did not modify AZT levels in maternal blood. 
 -Chronic in-utero exposure to AZT did not alter mitochondria function. 
 -Chronic in-utero exposure to AZT did not alter mitochondria ultrastructure. 
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